30 closest matches · ranked by relevance
KRAS NP_004976.2:p.G12R · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Proportion of Participants With an Objective Response (Partial Response + Complete Response) — 0; 0; 0; 0 Proportion of participants
Lung Cancer, Non-Small Cell
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (INV) — 11.7; 11.4 Weeks — p=0.5197
Lungcancer
Primary: Recommended Dose in Milligrams Per Day for Binimetinib. — 30 mg
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed Per RECIST v1.1 — 0; 11 Participants
KRAS Gene Mutation · Metastatic Non-Squamous Non-Small Cell Lung Carcinoma · Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Incidence of Dose-limiting Toxicity (DLT) of Pembrolizumab and Trametinib Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0…
Non-Small Cell Lung Cancer · KRAS Mutation-Related Tumors
Primary: Objective Response Rate — 9 Participants
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Metastatic Colorectal Cancer · KRAS Gene Mutation
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 1; 3 Participants
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Metastatic Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v8 · Stage IVA Colorectal Cancer AJCC v8
Primary: Progression Free Survival (PFS) — 2.3; 2.2 months
Non Small Cell Lung Cancer
Primary: Overall Survival — 29; 27; 13; 13 Participants — p=0.2069
KRAS Gene Mutation · Metastatic Malignant Neoplasm in the Brain · Recurrent Non-Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 3.7 months
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 6; 14; 5; 14 Participants — p=0.73
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Minimal Residual Disease · KRAS G12D · KRAS G12R
Primary: The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 — 1; 3; 2; 2 Participants
Non Small Cell Lung Carcinoma
Primary: Progression Free Survival — 2.3; 4.0; 2.4; 2.1 Months — p=0.24
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0 Participants
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Objective Response Rate at Weeks 17 and 25 — 20; 14; 22; 14 percentage of participants
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Colorectal Cancer · Metastatic Colorectal Cancer · RAS Wild Type Colorectal Cancer
Primary: Maximum Tolerated Dose (Phase I) of CB-839 in Combination With Panitumumab and Irinotecan Hydrochloride — 800 mg
Solid Tumors, KRAS Mutation
Primary: Number of Patients With DLTs in the MTD Evaluation Period — 0; 0; 2 Participants
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Non-small Cell Lung Cancer Stage IV
Primary: Progression Free Survival Rate — 4; 0 Participants
Non Small Cell Lung Cancer · KRAS Gene Mutation
Primary: Maximum Tolerated Dose of Ponatinib, Phase I — 30 mg of ponatinib